

## Special Issue

# Novel Strategies to Identify and Eliminate Latent HIV Cells

### Message from the Guest Editor

Cutting-edge technologies have dramatically enhanced our understanding of HIV-1 infection at the single-cell level (for example, HIVseq, FINDseq, viral ASAPseq), facilitating remarkable progress in the field. Despite numerous setbacks in the quest for a cure, novel therapeutic approaches have already reached the clinical trial stage, and new strategies are continually being proposed and implemented (for example CRISPR, targeted lipid nanoparticles, broadly neutralizing antibodies, AZD5582, trimeric Env, TLR7 agonist, anti-HIV CAR-T and/or a combination of them). The objective of this Special Issue of *Viruses* is to examine and discuss recent advancements in the analysis of HIV-1 viral infection at the single-cell level, as well as the latest ongoing efforts in developing new cure strategies.

---

### Guest Editor

Dr. Francesco Andrea Procopio  
CHUV, Division of Immunology and Allergy, Lausanne University Hospital, 1011 Lausanne, Switzerland

---

### Deadline for manuscript submissions

closed (31 January 2026)



## Viruses

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.5  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/209735](https://mdpi.com/si/209735)

*Viruses*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[viruses@mdpi.com](mailto:viruses@mdpi.com)

[mdpi.com/journal/  
viruses](https://mdpi.com/journal/viruses)





# Viruses

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.5  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
viruses](https://mdpi.com/journal/viruses)



## About the Journal

### Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

---

### Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,  
National Cancer Institute, Frederick, MD 21702-1201, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

#### Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.2 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).